

Cardiac diastolic function after recovery from pre-eclampsia

P Soma-Pillay, MC Louw, AO Adeyemo, J Makin, RC Pattinson

Abstract

Background: Pre-eclampsia is associated with significant changes to the cardiovascular system during pregnancy. Eccentric and concentric remodelling of the left ventricle occurs, resulting in impaired contractility and diastolic dysfunction. It is unclear whether these structural and functional changes resolve completely after delivery.

Aims: The objective of the study was to determine cardiac diastolic function at delivery and one year post-partum in women with severe pre-eclampsia, and to determine possible future cardiovascular risk.

Methods: This was a descriptive study performed at Steve Biko Academic Hospital, a tertiary referral hospital in Pretoria, South Africa. Ninety-six women with severe pre-eclampsia and 45 normotensive women with uncomplicated pregnancies were recruited during the delivery admission. Seventy-four (77.1%) women in the pre-eclamptic group were classified as a maternal near miss. Transthoracic Doppler echocardiography was performed at delivery and one year post-partum.

Results: At one year post-partum, women with pre-eclampsia had a higher diastolic blood pressure ($p = 0.001$) and body mass index ($p = 0.02$) than women in the normotensive control group. Women with early onset pre-eclampsia requiring delivery prior to 34 weeks' gestation had an increased risk of diastolic dysfunction at one year post-partum (RR 3.41, 95% CI: 1.11–10.5, $p = 0.04$) and this was irrespective of whether the patient had chronic hypertension or not.

Conclusion: Women who develop early-onset pre-eclampsia requiring delivery before 34 weeks are at a significant risk of developing cardiac diastolic dysfunction one year after delivery compared to normotensive women with a history of a low-risk pregnancy.

Keywords: pre-eclampsia, diastolic function, left ventricular remodelling, pregnancy

Submitted 23/3/17, accepted 10/7/17

Published online 31/8/17

Cardiovasc J Afr 2018; 29: 26–31

www.cvja.co.za

DOI: 10.5830/CVJA-2017-031

Pre-eclampsia is a pregnancy-specific disorder characterised by new-onset hypertension and proteinuria after 20 weeks' gestation. Hypertensive disorders in pregnancy have been one of the top five causes of maternal mortality in South Africa for more than a decade.¹ It was previously believed that the complications of pre-eclampsia ended with the delivery of the foetus and placenta, however it is now well established that pre-eclampsia is a risk for future hypertension, ischaemic heart disease, stroke and venous thromboembolism.²

Pregnancy is associated with significant haemodynamic and hormonal changes affecting the cardiovascular system. There is a 20% increase in cardiac output by eight weeks' gestation.³ Peripheral vasodilatation leads to a 20 to 30% fall in systemic vascular resistance and a 40% increase in cardiac output. The heart undergoes remodelling, with an increase in left ventricular wall thickness and mass.⁴

Despite these changes, the left ventricular contractile function is maintained and any changes in cardiac geometry are rapidly reversible within three months post-partum in normotensive women.⁴ By contrast, vascular reactivity is augmented in pregnancies affected by pre-eclampsia.⁵ Pre-eclampsia results in a state of increased vascular stiffness, generalised vasoconstriction and a high total vascular resistance and low cardiac output compared to the changes seen in a normal pregnancy.⁵

Cardiac changes classically associated with pre-eclampsia are diastolic dysfunction and an after-load-mediated left ventricular remodelling of the maternal heart.^{6,8} The heart remodelling is a response to the increased systemic afterload in order to minimise myocardial oxygen demand and preserve left ventricular function.

About 20% of women with pre-term pre-eclampsia and severe disease undergo severe left ventricular hypertrophy with advanced cardiac dysfunction.⁹ Typically there is preservation of both left atrial geometry and function, and left ventricular systolic function.^{4,10} The right ventricle is also usually unaffected.¹⁰ Levels of brain natriuretic peptide (BNP) increase in pregnancies complicated by pre-eclampsia, and Fayers *et al.* have shown that the increase in BNP is accompanied by changes in left ventricular diastolic function.¹¹ Elevated BNP levels are possibly the result of myocardial remodelling and sub-clinical ventricular dysfunction that accompanies the severe vasoconstriction observed in pre-eclampsia.¹¹

Diastolic dysfunction is described as impaired left ventricular filling and may be present in the setting of normal or abnormal systolic function. Pre-clinical diastolic dysfunction is associated with the development of future heart failure and is a predictor

Cardiac Obstetric Unit, Department of Obstetrics and Gynaecology, University of Pretoria, Steve Biko Academic Hospital, Pretoria, South Africa

P Soma-Pillay, FCOG, Cert (Maternal and Foetal Med) SA, priya.soma-pillay@up.ac.za

AO Adeyemo, MB BS, MCFP (SA), FCP (SA), Cert Cardiol (SA)

Department of Cardiology, University of Pretoria, Steve Biko Academic Hospital, Pretoria, South Africa

MC Louw, N Dip Clin Technol, B Tech Clin Technol; Cardiology

MediClinic Heart Hospital, Pretoria, South Africa

AO Adeyemo, MB BS, MCFP (SA), FCP (SA), Cert Cardiol (SA)

South African Medical Research Council Maternal and Infant Health Care Strategies Unit, Department of Obstetrics and Gynaecology, University of Pretoria, Pretoria, South Africa

P Soma-Pillay, FCOG, Cert (Maternal and Foetal Medicine) SA
J Makin, MB BCh, MSc (Epidemiology and Biostatistics)
RC Pattinson, MD, FRCOG, FCOG (SA)

of all-cause mortality.¹² Diastolic filling abnormalities may also play a significant role in the pathogenesis of pulmonary oedema, complicating hypertensive crises in pregnancy.¹³

Desai *et al.* found that diastolic filling abnormalities were demonstrated in a significant proportion of pre-eclamptic pregnancies complicated by pulmonary oedema compared to control groups of women who were hypertensive and normotensive in pregnancy.¹³ The authors of this study postulated that the diastolic filling abnormalities demonstrated in the study occurred within a short time frame of severe pre-eclampsia in pregnancy or could represent pre-eclampsia superimposed on established hypertension.

Whether diastolic dysfunction persists after delivery is uncertain. Identifying factors that may affect future cardiovascular risk may identify a group of women requiring increased post-partum vigilance and lifestyle modification. The aim of this study was to determine cardiac diastolic function at delivery and one year post-partum in women with severe pre-eclampsia and to further determine possible future cardiovascular risk.

Methods

This was a descriptive study of women with severe pre-eclampsia, performed at Steve Biko Academic Hospital from 1 April 2013 to 30 March 2016. The Cardiology Department at Steve Biko Academic Hospital reserved echocardiographic appointments every Wednesday during the study period. Post-partum women with severe pre-eclampsia were identified on a Wednesday morning and if fit to be transported to the cardiology clinic,

were informed of the study. Echocardiographic studies were performed on patients who consented to the procedure and were agreeable to follow-up studies.

One hundred and six women with severe pre-eclampsia and 45 normotensive, low-risk women who served as the control group were identified and recruited shortly after delivery. Women with structural heart disease or pulmonary embolus were excluded from the study. Women diagnosed with maternal metabolic syndrome were not recruited to the control group.

Echocardiograms of the maternal heart were performed between day two and seven post-delivery and follow-up scans were done after one year. Hypertensive disorders were classified according to the classification and diagnosis of the International Society for the Study of Hypertension in Pregnancy (ISSHP).¹⁴

Doppler echocardiography was carried out by the Department of Cardiology at Steve Biko Academic Hospital. The following echocardiographic parameters were assessed in the evaluation of diastolic dysfunction: left ventricular ejection fraction (LVEF), mitral E-wave (E) and mitral A-wave velocities (A), E/A ratio, mitral E-velocity deceleration time (DT), lateral early diastolic (e') velocity tissue Doppler and E/e' ratio.

The diagnosis of diastolic dysfunction was made by a clinician in the cardiac-obstetric unit. All women diagnosed with diastolic dysfunction had the following minimum positive criteria: average E/e' > 14 and lateral e' velocity < 10 cm/s. The American Society of Echocardiography and the European Association of Cardiovascular Imaging have described the advantages and limitations used to assess left ventricular diastolic function¹⁵ (Table 1).

Table 1. Utility, advantages and limitations of variables used to assess left ventricular diastolic function¹⁵ (reproduced with permission)

Variable	Physiological background	Advantages	Limitations
Mitral E velocity	Reflects the LA–LV pressure gradient during early diastole and is affected by alterations in the rate of LV relaxation and LAP	Feasible and reproducible	Directly affected by alterations in LV volumes and elastic recoil. Age dependent
Mitral A velocity	Reflects the LA–LV pressure gradient during late diastole, which is affected by LV compliance and LA contractile function	Feasible and reproducible	Sinus tachycardia, first-degree AV block and paced rhythm can result in fusion of the E and A waves. If mitral flow velocity at the start of the atrial contraction is > 20 cm/s, A velocity may be increased. Age dependent
Mitral E/A ratio	Mitral inflow E/A ratio and DT are used to identify the filling patterns	Feasible and reproducible. Provides diagnostic and prognostic information. A restrictive filling pattern in combination with LA dilatation in patients with normal EFs is associated with a poor prognosis similar to a restrictive pattern in dilated cardiomyopathy	The U-shaped relationship with LV diastolic function makes it difficult to differentiate normal from pseudonormal filling, particularly with normal LVEF, without additional variables. If mitral flow velocity at the start of atrial contraction is > 20 cm/s, E/A ratio will be reduced due to fusion. Age dependent
Mitral E-velocity DT	DT is influenced by LV relaxation, LV diastolic pressures following mitral valve opening, and LV stiffness	Feasible and reproducible. A short DT in patients with reduced LVEF indicates increased LVEDP with high accuracy both in sinus rhythm and in AF	DT does not relate to LVEDP in normal LVEF. Should not be measured with E and A fusion due to potential inaccuracy. Age dependent
Pulsed-wave TDI-derived mitral annular early diastolic velocity: e'	A significant association is present between e' and the time constant of LV relaxation shown in both animals and humans. The haemodynamic determinants of e' velocity include LV relaxation, restoring forces and filling pressure	Feasible and reproducible. LV filling pressures have a minimal effect on e' in the presence of impaired LV relaxation. Less load dependent than conventional blood-pool Doppler parameters	Need to sample at least two sites with precise location and adequate size of sample volume. Different cut-off values depending on the sampling site for measurement. Age dependent
Mitral E/e' ratio	e' velocity can be used to correct for the effect of LV relaxation on mitral E velocity, and E/e' ratio can be used to predict LV filling pressures	Feasible and reproducible. Values for average E/e' ratio < 8 usually indicate normal LV filling pressures, values > 14 have high specificity for increased LV filling pressures	E/e' ratio is not accurate in normal subjects, patients with heavy annular calcification, mitral valve and pericardial disease. 'Gray zone' of values in which LV filling pressures are indeterminate. Different cut-off values depending on the sampling site for measurement

LV, left ventricular; LA, left atrial; LAP, left atrial pressure; LVEF, left ventricular ejection fraction; DT, mitral E-velocity deceleration time; e', lateral early diastolic velocity; AF, atrial fibrillation.

Descriptive statistics in the form of means and standard deviations in the case of continuous data, and frequencies and percentages in the case of categorical data were calculated. A p -value of < 0.05 was considered significant. Ethical approval for the study was obtained from the University of Pretoria Ethics Committee (No. 125/2013).

Results

There were 6 536 deliveries at our hospital during the recruitment phase of the study (1 April 2013 – 30 March 2015). Four hundred and sixty-three (7.1%) women presented with severe pre-eclampsia and 106 women were recruited to the study. Ten women were lost to follow up. Data were therefore recorded for 96 women with severe pre-eclampsia and 45 controls.

Seventy-four (77.1%) women in the study group for whom data were available fulfilled the World Health Organisation (WHO) criteria for the classification of a maternal near miss. Of the 96 women with severe pre-eclampsia, 14 were diagnosed with chronic hypertension and four with diabetes prior to pregnancy. At one year, the mean diastolic blood pressure and mean body mass index was significantly higher among the women who had pre-eclampsia during pregnancy compared to the normotensive control group. Table 2 describes the demographic data of the study population.

Twenty women (20.83%) with pre-eclampsia were diagnosed with diastolic dysfunction at delivery compared with six (13.3%) of the controls ($p = 0.26$). Of the 20 women who were diagnosed with diastolic dysfunction at delivery, 13 (65%) had early-onset pre-eclampsia, requiring delivery prior to 34 weeks. At one year, 11 (11.46%) women with pre-eclampsia were diagnosed with diastolic dysfunction compared with three (6.67%) in the control group (RR = 1.67; $p = 0.27$).

Table 2. Demographic data of the study population

Characteristics	Pre-eclamptic group (n = 96)	Control group (n = 45)	p-value
Age, years			
Mean (SD)	28.9 (6.83)	27.2 (7.14)	0.66
Range	18–46	20–42	
Race			
African, n (%)	86 (89.58)	38 (84.44)	
Caucasian, n (%)	5 (5.20)	3 (6.67)	
Coloured, n (%)	4 (4.17)	4 (8.89)	
Indian, n (%)	1 (1.04)	0 (0)	
Obstetric history			
Parity mean (range)	1.3 (0–4)	1.6 (0–5)	
Timing of delivery			
< 34 weeks, n (%)	44 (45.83)	0 (0)	
34–37 weeks, n (%)	25 (26.04)	5 (11.11)	
> 37 weeks, n (%)	27 (28.13)	40 (88.89)	
Medical conditions			
Diabetic at 1 year, n (%)	6 (6.25)	0 (0)	
Hypertensive at 1 year, n (%)	52 (54.17)	2 (4.44)	
Haemoglobin at 1 year (g/dl)			
Mean (SD)	12.02 (1.46)	12.42 (1.13)	0.15
Blood pressure at 1 year (mmHg)			
Systolic, mean (SD)	128.01 (14.17)	115.08 (9.89)	0.08
Diastolic, mean (SD)	80.91 (14.47)	72.45 (9.16)	0.001
BMI at 1 year, mean (SD)	30.27 (7.55)	28.04 (3.64)	0.02

Women with early-onset pre-eclampsia requiring delivery prior to 34 weeks' gestation had an increased risk of diastolic dysfunction at one year post-partum (RR 3.41, 95% CI: 1.11–10.5, $p = 0.04$) (Fig. 1). Delivery prior to 34 weeks was associated with an increased risk of diastolic dysfunction even if patients with chronic hypertension at one year were excluded from the analysis ($p = 0.02$, 95% CI: 1.43–97.67). There was no significant association between diastolic dysfunction and chronic hypertension at one year (RR = 2.02, $p = 0.33$, 95% CI: 0.57–7.13). Echocardiographic measurements of diastolic function after one year are shown in Table 3.

Left ventricular systolic function was normal and similar in both groups, suggesting preservation of systolic function in both pre-eclampsics and controls. There was a significant decrease in lateral e' and a significant increase in A velocity between the pre-eclamptic and control group at one year.

Discussion

Heart failure is a progressive condition, which begins with risk factors for left ventricular dysfunction and progresses further to asymptomatic changes in cardiac structure and function, finally evolving into heart failure.¹⁶ Myocardial remodelling starts before the onset of symptoms. Diastolic dysfunction precedes the onset of systolic dysfunction in 50% of cardiac diseases, which further precedes the onset of heart failure.⁵

The American College of Cardiology has highlighted the importance of identifying asymptomatic cardiac dysfunction for early intervention and improvement of outcome.¹⁷ The risk for left ventricular diastolic dysfunction is significantly associated with higher age, body mass index (BMI), heart rate and systolic blood pressure.¹⁶ The prevalence of diastolic dysfunction in a general population aged less than 49 years was found to be 6.8%, and 27.3% for the total population, which included study subjects older than 70 years.¹⁶

Zanstra *et al.* found that 24% of women with the metabolic syndrome during pregnancy had diastolic dysfunction at six months post-partum, compared to 6.3% of women with low-risk pregnancies.¹⁸ Obesity and diastolic hypertension were strong correlates to diastolic dysfunction.

The rate of diastolic dysfunction at one year in the two groups of women with early-onset pre-eclampsia (22.7%) and low-risk pregnancies (6.7%) in our study were similar to rates




Fig. 1. Risk of diastolic dysfunction at delivery and at one year, and at one year for sub-group of women with early-onset pre-eclampsia requiring delivery prior to 34 weeks.

Table 3. Cardiac diastolic function at one year

	Pre-eclamptic group, mean (SD)	Control group, mean (SD)	p-value
Left ventricular ejection fraction, %	60.54 (7.62)	63.43 (4.88)	0.08
E velocity, m/s	0.98 (0.20)	0.95 (0.14)	0.90
A velocity, m/s	0.70 (0.24)	0.64 (0.05)	0.01
E/A ratio	1.42 (0.39)	1.46 (0.12)	0.74
E-deceleration time (ms)	224.57 (51.00)	225.43 (35.09)	0.08
Lateral e' (cm/s)	10.83 (2.86)	11.80 (1.99)	0.02
E/e' ratio	10.11 (5.32)	9.96 (2.25)	0.11

reported by Zanstra *et al.*¹⁶ Although our study did not find associations between diastolic blood pressure and obesity with diastolic dysfunction, women in the pre-eclamptic group had a significantly higher BMI and diastolic blood pressure than those in the control group. Additionally, diastolic dysfunction is also a risk factor for future death.

The Olmsted study described the predictive significance of left ventricular diastolic dysfunction using multivariable-adjusted analyses.¹⁹ The hazard ratio for all-cause mortality was 8.31 ($p < 0.001$) for mild diastolic dysfunction and 10.17 for moderate to severe diastolic dysfunction ($p < 0.001$). At one year post-delivery, diastolic dysfunction was present in 11.5% of women with pre-eclampsia, in 22.7% of women with early-onset pre-eclampsia and in 1.9% of women whose pre-eclampsia developed after 34 weeks. Women with early-onset pre-eclampsia requiring delivery prior to 34 weeks, irrespective of the presence of chronic hypertension, were at risk of developing diastolic dysfunction at one year post-delivery. Chronic hypertension, therefore, was not an additional risk factor for diastolic dysfunction at one year in women with early-onset pre-eclampsia.

This study found that early-onset pre-eclampsia was a risk factor for diastolic dysfunction, while women who developed pre-eclampsia after 34 weeks had a risk similar to that of low-risk parous women (RR 3.41, 95% CI: 1.11–10.5, $p = 0.04$). This may be explained by the proposed differences in pathophysiology between early- and late-onset pre-eclampsia.

Redman *et al.* have suggested that pre-eclampsia could be the result of intrinsic or extrinsic placental causes.²⁰ In early-onset pre-eclampsia, factors extrinsic to the placenta affect the uteroplacental circulation via incomplete spiral artery remodelling, while in late-onset disease, intrinsic factors affect the size of the placenta, restricting intervillous perfusion.²⁰

The placentas of women with early-onset disease differ significantly from those who develop pre-eclampsia at term.²¹ The former group demonstrate placental findings consistent with insufficiency and vascular lesions, while late-onset disease is characterised by placental hyperplasia and unimpaired foetal growth.^{21–24} Further evidence suggesting that pre-eclampsia is more than one disease comes from differences in biochemical markers, Doppler studies and clinical features of the disease.^{25–30}

Pre-eclampsia is a known risk factor for future chronic hypertension. Hypertension and hypertensive heart disease are one of the key contributors to the burden of non-communicable cardiovascular disease in Africa. Young African women are bearing the brunt of this increasing public health problem.^{31,32} Several studies have found that women from sub-Saharan Africa have the greatest risk of developing pre-eclampsia and eclampsia.^{33,34}

Nakimuli *et al.*, in a study of pre-eclampsia in women of African ancestry, found that African ancestry was the second strongest risk factor for pre-eclampsia after chronic hypertension.³⁵ African ancestry was also a risk factor for early-onset pre-eclampsia and poor obstetric outcomes such as foetal growth restriction and stillbirth.³⁵ Pregnancy-related deaths from pre-eclampsia are also three times higher in women of African ancestry compared with Europeans.³⁶ Almost 90% of women in our study were of African origin.

It is estimated that for every woman who dies during pregnancy or childbirth, 20 others will suffer severe morbidity.³⁷ Most maternal mortality and morbidity datasets record information for up to 42 days post-partum. However women who develop pre-eclampsia during pregnancy, especially those with early-onset disease, may develop heart failure several years after pregnancy, resulting in the problem not being adequately identified and addressed.

The prognosis of women with compromised cardiac function is poorer than that of men.¹⁸ Women often present with atypical symptoms, resulting in delayed presentation, delayed diagnosis and suboptimal care compared to men.^{38,39} These factors highlight the need to identify women at risk of future cardiovascular disease, with the aim of reducing potential modifiable risk factors. Blood pressure control, weight loss and a low-sodium diet are important measures that have been identified with favourable changes in ventricular diastolic function.¹⁸ The American Heart Association Guideline on Lifestyle Management to reduce cardiovascular risk for adults who would benefit from blood pressure lowering include dietary modification appropriate to calorie requirements, reduction in salt intake and three to four sessions of aerobic activity per week lasting on average 40 minutes per session.⁴⁰

This is the first study to evaluate diastolic function in a pre-eclamptic group of predominantly African population. Although we did not look at other risk factors for cardiovascular disease in this population, the study provides valuable information in identifying a potential group of women at risk of disease at an early stage. This would provide opportunities for screening and lifestyle modification.

The strength of this study is that it is one of the first to look at cardiac diastolic function in an African population where the rates of hypertension both during and outside of pregnancy were high. A possible limitation is that most patients were seen for the first time during pregnancy, with severe acute hypertension. Only 14.6% of women were known to have chronic hypertension. It is possible that some women had undiagnosed chronic hypertension – this is especially likely as the rate of chronic hypertension postpartum at one year was 54.2%. Some of the women with undiagnosed chronic hypertension may have had pre-existing diastolic dysfunction that could have been worsened by the superimposed pre-eclampsia. A further limitation is that only a select group of pre-eclamptic women were recruited to the study.

Conclusion

Women who develop early-onset pre-eclampsia requiring delivery prior to 34 weeks' gestation have an increased risk of cardiac diastolic dysfunction one year after delivery. Diastolic dysfunction precedes the onset of systolic dysfunction and

clinical heart failure. A strategy to screen and treat women with cardiovascular risk, particularly in lower- and middle-income countries should be explored further.

References

- Pattinson RC (ed). Saving Mothers 2011–2013: Sixth Report on Confidential Enquiries into Maternal Deaths in South Africa. Pretoria: Department of Health, 2014.
- Bellamy L, Casas JP, Hingorani AD, Williams D. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. *Br Med J* 2007; **335**: 974.
- Soma-Pillay P, Nelson Piercy C, Tolppanen H, Mebazaa A. Physiological changes in pregnancy. *Cardiovasc J Afr* 2016; **27**: 89–94.
- Simmons LA, Gillin AG, Jeremy RW. Structural and functional changes in left ventricle during normotensive and preeclamptic pregnancy. *Am J Physiol Heart Circ Physiol* 2002; **283**: H1627–H1633.
- Melchiorre K, Thilaganathan B. Maternal cardiac function in preeclampsia. *Curr Opin Obstet Gynecol* 2011; **23**: 440–447.
- Borghesi C, Esposti DD, Immordino V, et al. Relationship of systemic hemodynamics, left ventricular structure and function, and plasma natriuretic peptide concentrations during pregnancy complicated by preeclampsia. *Am J Obstet Gynecol* 2000; **183**: 140–147.
- Ingec M, Yilmaz M, Gundogdu F. Left atrial mechanical functions in preeclampsia. *J Obstet Gynaecol Res* 2005; **31**: 535–539.
- Hamad RR, Larsson B, Pernow J, et al. Assessment of left ventricular structure and function in preeclampsia by echocardiography and cardiovascular biomarkers. *J Hypertens* 2009; **27**: 2257–2264.
- Melchiorre K, Sutherland GR, Baltabaeva A, et al. Maternal cardiac dysfunction and remodelling in women with preeclampsia at term. *Hypertension* 2011; **57**: 85–93.
- Dennis AT, Castro JM. Echocardiographic differences between preeclampsia and peripartum cardiomyopathy. *Int J Obstet Anesth* 2014; **23**: 260–266.
- Fayers S, Moodley J, Naidoo DP. Cardiovascular haemodynamics in pre-eclampsia using brain natriuretic peptide and tissue Doppler studies. *Cardiovasc J Afr* 2013; **24**(4): 130–136.
- Wan SH, Vogel MW, Chen HH. Pre-clinical diastolic dysfunction. *J Am Coll Cardiol* 2014; **63**: 407–416.
- Desai DK, Moodley J, Naidoo DP, Borhat I. Cardiac abnormalities in pulmonary oedema associated with hypertensive crises in pregnancy. *Br J Obstet Gynaecol* 1996; **103**: 523–528.
- Tranquilli AL, Dekker G, Magee L, Roberts J, Sibai BM, Steyn W, et al. The classification, diagnosis and management of the hypertensive disorders of pregnancy: A revised statement from the ISSHP. *Preg Hypertens: Int J Women's Cardiovasc Health* 2014; **4**: 97–104.
- Nagueh SF, Smiseth OA, Appleton CP, Byrd BF, Dokainish H, Edvardsen T, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr* 2016; **29**: 277–314.
- Kuznetsova T, Herbots L, Lopez B, Jin Y, Richart T, Thijs L, et al. Prevalence of left ventricular diastolic dysfunction in a general population. *Circ Heart Fail* 2009; **2**: 105–112.
- Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiatas TG. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult. A report of the American College of Cardiology/American Heart Association Task Force on practical guidelines, 2005. Available at American College of Cardiology web-site (www.acc.org/qualityandscience/clinical/topic/ topic.htm).
- Zanstra M, Stekinger E, van der Vlugt MJ, van Dijk AP, Lotgering FK, Spaanderman MEA. Cardiac diastolic dysfunction and metabolic syndrome in young women after placental syndrome. *Obstet Gynecol* 2010; **115**: 101–108.
- Redfield MM, Jacobsen SJ, Burnett JC, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community. Appreciating the scope of the heart failure epidemic. *J Am Med Assoc* 2003; **289**: 194–202.
- Redman CW, Sargent IL, Staff AC. IFPA senior award lecture: Making sense of pre-eclampsia – Two placental causes of preeclampsia? *Placenta* 2014; **28**: S20–S25.
- Nelson DB, Ziadie MS, McIntire DD, Rogers BB, Leveno KJ. Placental pathology suggesting that preeclampsia is more than one disease. *Am J Obstet Gynecol* 2014; **210**: 66.e1–67.
- Vatten LJ, Skjaervan R. Is pre-eclampsia more than one disease? *Br J Obstet Gynaecol* 2004; **111**: 298–302.
- Moldenhauer JS, Stanek J, Warshak C, Houry J, Sibai B. The frequency and severity of placental findings in women with preeclampsia are gestational age dependent. *Am J Obstet Gynecol* 2004; **189**: 1173–1177.
- Ogge G, Chaiworapongsa T, Romero R, et al. Placental lesions associated with maternal underperfusion are more frequent in early-onset than in late-onset preeclampsia. *J Perinatal Med* 2011; **39**: 641–652.
- Gupta AK, Gebhardt S, Hillerman R, Holzgreve W, Hahn S. Analysis of plasma elastase levels in early and late onset preeclampsia. *Arch Gynecol Obstet* 2006; **273**: 239–242.
- Crispi F, Llorca E, Dominguez C, Martin-Gallan P, Cabero L, Gratacos E. Predictive value of angiogenic factors and uterine artery Doppler for early- versus late-onset pre-eclampsia and intra-uterine growth restriction. *Ultrasound Obstet Gynecol* 2008; **31**: 303–309.
- Yu CK, Smith GC, Papageorghiou AT, Cacho AM, Nicolaides KH; Fetal Medicine Foundation Second Trimester Screening Group. An integrated model for the prediction of preeclampsia using maternal factors and uterine artery Doppler velocimetry in unselected low-risk women. *Am J Obstet Gynecol* 2005; **193**: 429–436.
- Melchiorre K, Womald B, Leslie K, Bhide A, Thilaganathan B. First trimester uterine artery Doppler indices in term and preterm preeclampsia. *Ultrasound Obstet Gynecol* 2008; **32**: 133–137.
- Audibert F, Boucoiran I, An N, et al. Screening for preeclampsia using first-trimester serum markers and uterine artery Doppler in nulliparous women. *Am J Obstet Gynecol* 2010; **203**: 383e1–388.
- Borzychowski AM, Sargent IL, Redman CW. Inflammation and preeclampsia. *Semin Fetal Neonatal Med* 2006; **11**: 309–316.
- Sliwa K, Ojji D, Bachelier K, Bohm M, Damasceno A, Stewart S. Hypertension and hypertensive heart disease in African women. *Clin Res Cardiol* 2014; **103**: 515–523.
- Ntusi NB, Badri M, Gumede F, Sliwa K, Mayosi BM. Pregnancy-associated heart failure: a comparison of clinical presentation and outcome between hypertensive heart failure of pregnancy and idiopathic peripartum cardiomyopathy. *PLoS One* 2015; **10**(8): e0133466. doi: 10.1371/journal.pone.0133466.
- Urquia ML, Glazier RH, Gagnon AJ, Mortensen LH, Nybo, Andersen A-MN, et al. Disparities in pre-eclampsia and eclampsia among immigrant women giving birth in six industrialised countries. *Br J Obstet Gynaecol* 2014; **121**: 1492–1500.
- Abalos E, Cuesta C, Carroli G, Qureshi Z, Widmer M, Souza JP, et al. Pre-eclampsia, eclampsia and adverse maternal and perinatal outcomes: a secondary analysis of the World Health Organisation Multicountry Survey on Maternal and Newborn Health. *Br J Obstet Gynaecol* 2014; **121**(Suppl. 1): 14–24.

35. Nakimuli A, Chazara O, Byamugisha J, Elliott AM, Kaleebu P, Mirembe F, *et al.* Pregnancy, parturition and preeclampsia in women of African ancestry. *Am J Obstet Gynecol* 2014; **207**: 510–520
36. MacKay AP, Berg CJ, Atrash HK. Pregnancy-related mortality from preeclampsia and eclampsia. *Obstet Gynecol* 2001; **97**: 533–538.
37. Health Canada. Special Report on Maternal Mortality and Severe Morbidity in Canada – Enhanced Surveillance: the Path to Prevention. Ottawa: Minister of Public Works and Government Services Canada, 2004.
38. Barakat K, Wilkinson P, Suliman A, Ranjadayalan K, Timmis A. Acute myocardial infarction in women: contribution of treatment variables to adverse outcome. *Am Heart J* 2000; **140**: 740–746.
39. Daly C, Clemens F, Lopez Sandon JL, Tavizzi L, Boersma E, Danchin N, *et al.* Euro Heart Survey Investigators. Gender differences in the management of acute myocardial infarction, 1994 through 2002. *N Engl J Med* 2005; **353**: 671–682.
40. Hummel SL, Seymour EM, Brook RD, Sheth SS, Ghosh E, Zhu S, *et al.* Low-sodium DASH diet improves diastolic function and ventricular-arterial coupling in hypertensive heart failure with reserved ejection fraction. *Circulation: Heart Fail* 2013; **6**:1165–1171.

Ten-year fall in blood cholesterol of Malaysia heart attack patients suggests statin impact

A 10-year decline in the blood cholesterol of heart attack patients in Malaysia suggests that statins are having a positive impact, according to an observational study in nearly 49 000 patients presented at the ASEAN Federation of Cardiology Congress 2017 (AFCC2017).

AFCC2017 was hosted by the Brunei Cardiac Society, with the support of the ASEAN Federation of Cardiology, on 3 to 5 November in Brunei Darussalam. Experts from the European Society of Cardiology (ESC) presented a special programme.

‘Lifestyle changes appear to be responsible for falls in blood cholesterol in the general populations of developed nations while statins have reduced cholesterol in patients with heart disease,’ said lead author Dr Sazzli Kasim, Chair, Malaysian Society of Atherosclerosis and Associate Professor of Medicine, University Technology MARA, Shah Alam, Malaysia.

‘Blood cholesterol is still on the rise in the general population of developing countries like Malaysia,’ he continued. ‘This study investigated trends in cholesterol levels in Malaysian patients with acute coronary syndromes.’

The study included 48 851 patients who had an acute coronary syndrome between 2006 and 2015 in Malaysia and were enrolled in the National Cardiovascular Disease Database Acute Coronary Syndrome (NCVD-ACS) registry. This ongoing registry is maintained by the National Heart Association Malaysia with the support of the Ministry of Health Malaysia. Total cholesterol was assessed on entry to the registry.

The researchers examined trends in cholesterol levels of ACS patients over the 10-year period and compared them to previously published values for the entire population. They found a significant trend for declining total cholesterol from 2006 to 2015 in the ACS population ($p = 0.012$). This was opposite to the total cholesterol trend in the Malaysian population.

ACS patients with a history of coronary heart disease had almost twice the declining rate in cholesterol as those with

no history of coronary heart disease. When the researchers examined total cholesterol by type of ACS, they found that patients with unstable angina had the lowest total cholesterol level but the steepest rate of decline, followed by patients with non-ST-elevation myocardial infarction and then patients with ST-elevation myocardial infarction.

Dr Kasim said: ‘We found that blood cholesterol levels have been falling in Malaysian patients with acute coronary syndromes, which is the opposite of the national trend.’

‘Since cholesterol levels have increased significantly in the Malaysian population as a whole, it is highly doubtful that lifestyle change is the reason for the declining cholesterol trend we observed in the ACS population,’ he continued.

Dr Kasim said: ‘While this was an observational study and we cannot infer causality, it seems likely that cholesterol levels decreased as a result of lipid-lowering medication such as statins. ACS patients with a history of coronary heart disease, who were more likely to be taking statins, had a more rapid decline in cholesterol levels than those without a history of coronary heart disease.’

He concluded: ‘These results appear to mimic findings from developed countries in previous years and show that the Malaysian population is reaching similar health milestones. The findings also highlight the need to increase awareness of the harm of raised lipid values and the treatment available.’

Dr Ezam Emran, scientific chair of AFCC 2017, said: ‘This large study suggests that statins are being effectively used by heart attack patients in Malaysia. Rising lipid levels in the general population need to be tackled by promoting healthier lifestyles.’

Professor Michel Komajda, a past president of the ESC and course director of the ESC programme in Brunei, said: ‘The benefits of statins for preventing a second heart attack are unequivocal, as highlighted by the 2017 ESC guidelines. Patients should also be encouraged to quit smoking, adopt a healthier diet and be physically active.’

Source: European Society of Cardiology Press Office